PO-0698: Clinical outcomes of 4D CBCT-guided stereotactic body radiotherapy for inoperable hepatocellular carcinomas  by Chiang, C.L. et al.
S342                                                                                                                                         3rd ESTRO Forum 2015 
 
PO-0696   
Mutational analysis by next generation sequencing in 
patients with biliary and pancreatic adenocarcinoma  
A.L.H. Arnett1, K. Chang1, T.T. Sio1, R.J. Miller2 
1Mayo Clinic, Radiation Oncology, Rochester, USA  
2Mayo Clinic, Radiation Oncology, Jacksonville, USA  
 
Purpose/Objective: In this retrospective study, next-
generation exomic sequencing (NGS) was utilized in biliary 
and pancreatic adenocarcinoma samples to identify potential 
novel therapeutic targets that are not routinely assayed in 
the clinical setting. 
Materials and Methods: Patients with confirmed pancreatic 
adenocarcinoma or cholangiocarcinoma were selected based 
on availability of tissues. A total of 236 somatic genes were 
surveyed in this review, including 3,230 exons and 47 introns 
at >900x mapping coverage. NGS reports were generated 
from 2011 to 2013 and reviewed restrospectively. Statistical 
analysis was performed using univariate analysis and Kaplan-
Meier survival estimates.  
Results: Seventeen (95%) of cases harbored at least one 
potentially actionable mutation, including BRACA (10.5%), 
CDKN2 (26.3%), FGFR (15.8%), KRAS (42.1%), MLL (26.3%), 
NRAS (5.3%), PIK3CA (10.5%), and TP53 (42.1%). Notably, 
KRAS mutations were found at a higher frequency in 
pancreatic adenocarcinomas in comparison to 
cholangiocarcinomas (87.5% vs 9.1%). Overall, the most 
frequent genomic alterations were found within KRAS 
(42.1%), TP53 (42.1%), CDKN2 (26.3%), and MLL (26.3%). All 
patients with SMAD alterations were also found to have 
concurrent KRAS mutations, which is consistent with reported 
literature. KRAS mutations most commonly involved codon 
12, while the locations of SMAD and Tp53 mutations were 
heterogeneous. In addition, concurrent mutations were found 
within genes that have been shown to potentially modulate 
or interact with KRAS-mediated signaling pathways, including 
CCND3, CDKN2A/B, and RB1. Alterations of BCOR, CCND3, 
CRKL, NF1, STK11, and TSC1 were rare events (<6%). 
Furthermore, 95% of patients had multiple, novel mutations 
that have not been associated with pancreatic or biliary 
adenocarcinoma. The majority (63.2%) of patients had 
greater than five mutations identified. Median survival and 5-
yr OS in pancreatic adenocarcinoma were 30.1 months and 
41%, respectively. 5-yr OS in cholangiocarcinoma cases was 
substantially higher (85.7%), and 27.2% of these patients 
received EBRT as a component of their treatment. For either 
subset of patients, there was no significant correlation 
between number of mutations and OS. Overall, 63% of 
patients were found to have mutations associated with 
targeted therapies. One quarter of these patients possessed 
multiple, concurrent molecular targets for which FDA-
approved chemotherapeutic agents are currently available. 
Conclusions: Novel mutations were identified in the majority 
of patients, including mutations within a number of genes 
which have the potential to influence KRAS-mediated 
signaling, as well as other prominent signaling pathways. 
These results could potentially serve to identify targets for 
novel chemotherapeutic agents and to guide personalized, 
combinatorial therapy in appropriately selected patients.  
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Purpose/Objective: The aim of this study is to compare the 
failure model between esophageal carcinoma patients 
receiving elective nodal prophylactic irradiation and 
involved-field irradiation, and to explore the reason of failure 
and influence factors of local recurrence. 
Materials and Methods: From January 2006 to December 
2012,245 patients of esophageal carcinoma receiving 
definitive radiation therapy in our hospital were respectively 
analyzed. One hundred and twenty-six patients received 
elective nodal prophylactic irradiation(ENI),and the other 119 
patients received involved-field irradiation(IFI).Failure 
patterns were analyzed after treatment and long-term follow 
up. Local regional failure included esophagus lesion 
remaining or relapse and regional lymph nodes recurrence. 
Distance metastases included distant organ metastases and 
distant lymph node metastases. Multivariate analysis was 
performed by the Cox proportional hazard model. 
Results: The 1,3 and 5 years loco-regional control rates of 
ENI group and IFI group were 72.5%,52.8%,50.6% and 
58.4%,35.8%,21.9%(χ2=7.881,P=0.005) respectively. The 
1,3,and 5 years overall survival rates of the ENI group and IFI 
group were 74.3%,44.2%,24.5% and 68.9%,27.6%,15.9% 
(χ2=1.903,P=0.168). In Cox multivariate analysis, clinical T 
stage, tumor location, different radiotherapy region were 
independent factors for the loco-regional control of all 
patients. One hundred and sixty-three patients developed 
failure after treatment and follow-up. Simple loco-regional 
failure was observed in 92 patients, alone distant metastases 
was observed in 36 patients, and both regional failure and 
distant metastases was observed in 35 patients. The 1,3,and 
5 years total failure rates of ENI group and IFI group was 
35.4%,62.5%,69.0% and 46.5%,71.5%,81.5% respectively 
(χ2=4.402,P=0.036). The 1,3,and 5 years loco-regional failure 
rates of ENI and IFI group were 29.9%,48.4%,50.0% and 
39.6%,62.1%,71.4% respectively (χ2=8.638, P=0.003). 
Conclusions: The elective nodal prophylactic irradiation of 
esophageal carcinoma with receiving definitive treatment 
could reduce loco-regional failures and improve local control. 
Maybe in order to improve the long-term survival.  
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Purpose/Objective: To report the clinical outcomes of 
patients with inoperable hepatocellular carcinoma (HCC) 
receiving 4D cone-beam CT (4D CBCT) guided stereotactic 
body radiotherapy (SBRT) using lipiodol as tumor surrogate. 
Materials and Methods: From Jan-2012 to Dec-2013, thirty 
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patients with inoperable HCC (N=30) received single trans-
arterial chemoembolization (TACE) followed by volumetric-
modulated arc radiotherapy (VMAT)-based SBRT applying the 
van Herk margin recipe with mid-ventilation concept. Doses 
of SBRT were individualized according to normal tissue 
constraints. Tumor localization was performed by 4D CBCT 
using lipiodol as surrogate. Tumor responses were assessed by 
CT images using RECIST criteria every 3 months in the first 
year. In-field recurrence was defined as recurrence within 
the high-dose region (80% isodose volume). Overall survival, 
progression-free survival and local control rates were 
evaluated by the Kaplan-Meier method. Toxicities were 
graded according to CTCAE version 4.  
Results: Median follow-up time was 12 months (range: 4.2–
30.6 months). Patients’ characteristics were as follows: 
Median age (61 years, range: 28-87); Male/ female (n= 28/2); 
Child-Pugh class A/B (n= 28/2); ECOG 0-1/2 (n=21/9); BCLC 
stage A/B/C (n= 2/14/14); TNM stage I/II/III/IV 
(n=10/0/17/3); Solitary/ Multifocal (n=20/10); Portal vein 
thrombosis (n=8). Median size of tumor was 12.7cm (range: 
4.4-19.7cm) and Median GTV size was 937cc (range: 81-
3218cc). Median dose (2Gy equivalent, a/b=3) was 75Gy 
(range: 56-140Gy). Overall objective response rate was 67% 
(CR: n=1, PR: n=19). The 1-year in-field control, overall 
survival (OS) and progression-free survival (PFS) rate was 
86%, 65% and 42% respectively. Median survival not yet 
reached. Treatments were well tolerated. No grade 4-5 
toxicities were observed. Most common grade 3 toxicities 
were elevation of liver enzymes (n=6, 20%) and 
thrombocytopenia (n=1, 3%). No patient developed radiation-
induced liver disease (RILD).  
Conclusions: 4DCBCT guided SBRT using lipidiol as surrogate 
for tumor localization is feasible for inoperable HCC patients. 
It is safe, well tolerated and achieves high in-field control 
rate.  
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Purpose/Objective: Neo-adjuvant chemoradiotherapy (neo-
CRT) followed by surgery is currently the standard curative 
treatment for esophageal cancer. Both modalities may cause 
serious toxicity and morbidity. The aim of this study was to 
evaluate the incidence of pleural and pericardial effusion 
after neo-CRT followed by surgery and to investigate the 
impact on quality of life (QoL).  
Materials and Methods: Patients, that were included in a 
prospective trial to evaluate the impact of PET/CT for 
radiotherapy planning , underwent routine CT scanning 
during follow up in order to evaluate tumour recurrences. All 
these follow up CT's were blindly reviewed by a radiologist 
for signs of pleural and/or pericardial effusion. The degree of 
these toxicities was categorized as minor, moderate or 
severe. QoL questionnaires (EORTC QLQ-C30) were part of 
this follow up as well and were used to evaluate the impact 
of pleural and/or pericardial effusion . To investigate the 
relationship between pleural or pericardial effusion and the 
different domains of QoL a ANOVA was used. 
Results: Seventy-one patients were treated with neo-CRT and 
underwent routine CT scanning during follow up in absence of 
known recurrence and insufficient physical condition. The 
disease free survival (DFS) was 79%, 59% and 52% at 6, 12 and 
18 months after neo-CRT. At that time, 50, 42 and 35 
patients underwent follow up CT's. Pleural effusion occurred 
in 25 patients (50%) at 6 months and reduced over time; 33% 
at 12 months and 31% at 18 months. The degree was minor, 
moderate and severe in 11, 10 and 4 patients at 6 months. At 
18 months severe pleural effusion was still present in 3 
patients (9%). Pericardial effusion was seen in only 3 patients 
(6%) and completely reduced over time; 2.4% at 12 months 
and 0% at 18 months. Both pleural and pericardial effusion 
seemed of non-malignant origin, except for one patient with 
progressive malignant pleural effusion. Pleural effusion had a 
significant impact on physical functioning (p=0.001) and 
significantly enhanced dyspnoea (p=0.02). The mean score 
for physical functioning was 69 (SD: 26.3) in patients with 
pleural effusion vs. 82 (SD: 14.3) in absence of pleural 
effusion. Furthermore, pericardial effusion was significantly 




Conclusions: Pleural effusion is frequently observed after 
neo-CRT followed by surgical resection and improved over 
time and persisted up to 18 months pleural in 31% of the 
patients. Pericardial effusion is less common. Both pleural 
and pericardial effusions have a significant impact on QoL in 
terms of decreased physical functioning and increased 
dyspnoea.  
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